Opportunity
Federal Register #2026-23414
FDA Determination on BROMFED-DM’s Discontinuation and Safety Status
Buyer
Food and Drug Administration
Posted
November 18, 2026
Identifier
2026-23414
This FDA notice addresses the safety-status determination for BROMFED-DM and is not a government procurement opportunity. - Government agency: U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA). - FDA determination: BROMFED-DM syrup was not withdrawn from sale for reasons of safety or effectiveness. FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to the product and may continue approving qualifying ANDAs. - Product discussed: BROMFED-DM syrup, containing brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride. The listed strengths are 2 mg/5 mL, 10 mg/5 mL, and 30 mg/5 mL; it is indicated for cough and upper respiratory symptoms associated with allergies or the common cold. - Named parties: Pharmobedient Consulting LLC holds ANDA No. 088811; Steranco Healthcare Pvt. Ltd. submitted the citizen petition. No manufacturer or OEM is identified. - Procurement scope: No products or services are being solicited, and no purchase quantities or contract requirements are stated.
Description
The FDA determined that BROMFED-DM syrup in the listed strengths was not withdrawn from sale for reasons of safety or effectiveness. The determination means FDA will not begin procedures to withdraw approval of ANDAs referring to the product and may continue approving qualifying ANDAs. The notice concerns ANDA No. 088811, held by Pharmobedient Consulting LLC, and follows a citizen petition requesting the determination. The product is indicated for relief of coughs and upper respiratory symptoms associated with allergy or the common cold.